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ABSTRACT
Objectives To explore the acceptability of home visual 
field (VF) testing using Eyecatcher among people with 
glaucoma participating in a 6- month home monitoring pilot 
study.
Design Qualitative study using face- to- face 
semistructured interviews. Transcripts were analysed 
using thematic analysis.
Setting Participants were recruited in the UK through an 
advertisement in the International Glaucoma Association 
(now Glaucoma UK) newsletter.
Participants Twenty adults (10 women; median age: 
71 years) with a diagnosis of glaucoma were recruited 
(including open angle and normal tension glaucoma; mean 
deviation=2.5 to −29.9 dB).
Results All participants could successfully perform VF 
testing at home. Interview data were coded into four 
overarching themes regarding experiences of undertaking 
VF home monitoring and attitudes towards its wider 
implementation in healthcare: (1) comparisons between 
Eyecatcher and Humphrey Field Analyser (HFA); (2) 
capability using Eyecatcher; (3) practicalities for effective 
wider scale implementation; (4) motivations for home 
monitoring.
Conclusions Participants identified a broad range of 
benefits to VF home monitoring and discussed areas for 
service improvement. Eyecatcher was compared positively 
with conventional VF testing using HFA. Home monitoring 
may be acceptable to at least a subset of people with 
glaucoma.
INTRODUCTION
Glaucoma is a chronic progressive condition 
and a leading cause of non- recoverable vision 
loss. Worldwide prevalence of glaucoma is 
projected to reach ~111 million people aged 
40–80 years by 2040.1 Patients with glaucoma 
require lifelong clinical monitoring; in the 
UK this is typically within the hospital eye 
service. High patient caseload has resulted 
in glaucoma services struggling to accom-
modate demand; therefore, establishing new 
methods to support effective surveillance is 
required. The National Health Service (NHS) 
Long Term Plan, a 10- year strategy describing 
major practical changes to the NHS service 
model, aims to make home monitoring of 
chronic conditions a more widely established 
and convenient component of patient care.2 
In addition, with the COVID-19 pandemic 
reducing the number of in- clinic services 
available, improving remote services and 
home monitoring is a research priority.3
Assessment of functional damage in glau-
coma is determined through perimetry, a 
psychophysical test highlighting areas of 
reduced visual (luminance contrast) sensi-
tivity. This measurement, known as the visual 
field (VF) test, is used in combination with 
other clinical metrics to determine progres-
sion of disease, and analysis of serial tests 
can be used to estimate risk of severe visual 
loss.4–6 VF testing may also help predict how 
glaucoma will impact on patients’ quality of 
life over time.7
Home monitoring, whereby disease 
progression is proactively monitored through 
patient- led, home- based testing, may help 
alleviate the increasingly unsustainable 
burden on hospital eye services.8 9 Innova-
tion has increased opportunities to perform 
clinical tests at home.10 For example, home- 
based perimetry has been shown to be highly 
Strengths and limitations of this study
 ► This is the first study to collect in- depth qualitative 
data regarding the acceptability of home visual field 
monitoring in people with glaucoma.
 ► Our findings can be used to underpin future re-
search into glaucoma home monitoring and may 
guide decision- makers when implementing this 
healthcare service.
 ► The sample consisted of self- selected volunteers 
who were members of a glaucoma charity, poten-
tially limiting generalisability of the data.
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comparable with conventional hospital- based perim-
etry11 12 and may be inexpensive to implement. Other 
tangible benefits may include increased capacity to 
collect more frequent VF data, shortened hospital visits 
and strengthening of the overall glaucoma health service 
by intelligently prioritising patients.
Previous research suggests people with glaucoma are 
receptive to forms of home monitoring, such as web- 
based symptom diaries.13 However, the acceptability 
of home- based VF testing has not been explored. This 
research gap is significant as integration of new health-
care approaches can be challenging and sometimes met 
with resistance from service users.14 For home monitoring 
to be successful, clinical measurements must be accurate, 
and patients must be accepting of this healthcare model. 
We assessed accuracy of home VF monitoring in a parallel 
investigation.15 The aim of the present study was to inves-
tigate the acceptability of VF home monitoring using the 
Eyecatcher programme. This report focuses on under-
standing the experiences of patients with glaucoma of 
VF home monitoring for 6 months, and exploring views 




Participants were recruited via an advertisement in the 
International Glaucoma Association newsletter (IGA News: 
https://www. glaucoma- association. com/ about- the- iga/ 
what- we- do/ magazine) on a consecutive basis until the 
recruitment goal was reached. Participants were assessed 
for suitability by a glaucoma- accredited optometrist (PC). 
Twenty people (10 women) aged 62–78 (median: 71) 
years with an established diagnosis of glaucoma were 
recruited (table 1). Detail of clinical measurements and 
ocular findings are published elsewhere (Jones et al, 2021). 
Briefly, all participants recorded baseline best- corrected 
visual acuity <0.5 logMAR in the better eye. Worse eye (ie, 
most afflicted) VF loss as determined by Humphrey Field 
Analyser (HFA) mean deviation (MD) ranging from −2.4 
dB (early) to −30.0 dB (advanced), although the majority 
of eyes exhibited moderate loss (median: −8.9 dB). MD is 
a summary measure of overall reduction in VF sensitivity 
relative to a group of healthy age- matched observers, with 
more negative values indicating more vision loss. Written 
informed consent was obtained prior to enrolment.
Table 1 Participant demographics and ocular findings
Participant ID
Age 







      (at 
baseline)
P01 60–69 Male PACG Caucasian −4.2 −24.0 Y
P02 60–69 Female POAG Caucasian −2.9 −9.4 N
P03 70–79 Male POAG Caucasian −2.5 −3.0 N
P04 70–79 Female POAG Caucasian −3.4 −7.1 N
P05 60–69 Male POAG Caucasian −21.1 0.2 N
P06 70–79 Male NTG Caucasian −8.4 −10.2 Y
P07 70–79 Female POAG Caucasian −2.6 −15.2 Y
P08 60–69 Male NTG Caucasian −16.6 −2.7 Y
P09 70–79 Female POAG Caucasian −14.2 −1.0 N
P10 70–79 Female POAG Caucasian −30.0 −13.4 N
P11 70–79 Male POAG Caucasian −22.7 −11.9 N
P12 70–79 Male NTG Caucasian −3.6 −3.1 Y
P13 60–69 Female POAG Caucasian −7.9 −7.1 N
P14 60–69 Male NTG Caucasian −5.4 −2.4 Y
P15 70–79 Female NTG Caucasian −4.7 −3.9 Y
P16 60–69 Female POAG Caucasian −4.0 −0.3 Y
P17 60–69 Male POAG Caucasian −2.7 −10.0 Y
P18 70–79 Female NTG Caucasian −5.7 −7.3 N
P19 60–69 Male SOAG Caucasian −3.8 −0.6 Y
P20 70–79 Female POAG Caucasian −2.4 −2.0 N
HFA MD=average between two monocular tests at baseline.
HFA, Humphrey Field Analyser; MD, mean deviation; NTG, normal tension glaucoma; PACG, primary angle closure glaucoma; POAG, 
primary open angle glaucoma; SOAG, secondary open angle glaucoma.
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Procedure
The interviews were conducted as part of a wider investi-
gation of accuracy and adherence to home VF monitoring 
using Eyecatcher. The full study protocol is described in 
an earlier report15 and is briefly summarised here. Partic-
ipants were asked to perform VF testing using Eyecatcher 
at home once per eye, per month, for 6 months (12 tests 
total). Ten participants (50%) were randomly selected 
to practise Eyecatcher once in each eye, under supervi-
sion at baseline (table 1.). The rationale for dividing the 
sample in this way was to determine whether there were 
perimetric learning effects using Eyecatcher. We report in 
our parallel investigation there was no significant differ-
ence in mean absolute error between the eyes of partici-
pants who received a practice, and those who did not.15 All 
participants performed two HFA VF tests in each eye (24-2 
SITA Fast) at baseline and again after the 6- month home 
VF monitoring period was completed at City, University 
of London. All participants received email reminders 
when the tests were due and were provided with contact 
information for any queries. Eyecatcher VF tests were 
performed using a custom screen perimeter on a convert-
ible laptop/tablet (figure 1.). The test was a variant of 
the ‘Eyecatcher’ test described previously12 16 and closely 
mimicked conventional static threshold perimetry. Good 
concordance between VF tests at home using Eyecatcher 
and in the clinic using HFA perimetry was observed 
(figure 2). To date, the development of Eyecatcher has 
been funded in part by university research time and 
non- commercial research grants. The complete source 
code is available online (https:// github. com/ petejonze/ 
eyecatcher) under a non- commercial (General Public 
License V.3.0) licence.
Data collection
Semistructured interviews were conducted between 
January and March 2020 on completion of the 6- month 
home monitoring period. All but one of the interviews 
were carried out at City, University of London. Due to 
transport restrictions during the COVID-19 pandemic, 
one interview was performed via telephone. Interviews 
were carried out one- to- one by a male research fellow with 
a background in psychology (LJ; n=19) or a male glau-
coma specialist optometrist (PC; n=1). Interview duration 
ranged between 6 and 38 (median: 17) min. The interview 
topic guide (table 2) included questions on participants’ 
general attitudes toward home VF testing and questions 
regarding specific behaviours such as how VF home 
monitoring could be carried out and why. To understand 
key determinants of behaviour, the questions were guided 
by the COM- B model (Capability, Opportunity, and Moti-
vation for Behaviour) of the Behaviour Change Wheel 
framework.17 The framework was used to determine how 
VF home monitoring might be affected by individuals’ 
knowledge, skill, opportunity and motivations.
Data analysis
Audio- recordings were transcribed verbatim by a profes-
sional transcription service. LJ performed thematic 
analysis as described by Braun and Clarke,18 whereby tran-
scribed texts were read and re- read to ensure familiarity, 
and meaningful units were coded using primarily an 
inductive approach (ie, driven by the content of the data). 
A deductive approach was later used when considering the 
identified themes in relation to the COM- B framework 
which was used to collect subthemes into the respective key 
themes. Transcripts were coded at a semantic level, consid-
ering the explicit content of the data. Data were analysed 
using NVivo V.12 (QSR International, Cambridge, Massa-
chusetts, USA). Data saturation was determined post 
hoc and indicated further data collection or analysis was 
unnecessary. The coding framework was independently 
reviewed for suitability by a research optometrist (TC), 
Figure 1 Eyecatcher testing was performed using home- 
based perimeter hardware. Participants completed the 
test monocularly and were asked to respond each time a 
white dot appeared with a button press using the attached 
handheld control. The red central point marks the fixation 
cross. The purple arrow shows the built- in webcam used to 
observe anomalous tests.
Figure 2 Visual field (VF) testing regimen. Data shown are raw VF results at each test interval for one randomly selected eye. 
Darker tones represent decreasing visual sensitivity. The first and last columns show mean averaged data from two ‘pre’ and 
two ‘post’ reference tests, performed in clinic using a Humphrey Field Analyser (HFA). As described elsewhere,13 there was 
good concordance between Eyecatcher and HFA.
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who interpreted patterns in the identified themes and 
suggested amendments. Where there were differences in 
coding choices (34 occasions in 558 coded references), 
there was discussion with assistance of a third reviewer 
(DJT), and when consensus was reached the coding frame-
work was finalised. At this point, a member- checking exer-
cise was employed to assess the credibility and authenticity 
of the final coding framework. In line with recommended 
practice,19 all participants were emailed a word document 
of the coding framework which included the main themes 
and subthemes and anonymised quotations as illustrated 
in the results. Participants were given the opportunity 
to clarify or elaborate on any aspect of the framework 
and to describe if the interpretation was congruent with 
their experience. The process allowed for an assessment 
of descriptive validity (factual accuracy of accounts) and 
interpretive validity (accuracy in determining meaning of 
quotes). Of 20 participants, 14 responded during this exer-
cise and the manuscript was amended following recom-
mendations. Finally, the study was designed and reported 
following the guidance of the Consolidated Criteria for 
Reporting Qualitative Research.20
Patient and public involvement
The purpose and design of the study were described in a 
newsletter article from a charity for people with glaucoma 
(IGA), and the study outcomes will be disseminated to 
the wider glaucoma community in the same way. Three 
patients with glaucoma known to the research team 
reviewed the study design during the planning phase and 
provided feedback during a focus group. Study partici-
pants helped to steer this project during data analysis and 
reporting through the member- check exercise. Partici-
pant feedback will also help improve the design of future 
home VF monitoring studies.
RESULTS
All 20 participants enrolled in the study took part in a 
semistructured interview. Nineteen of 20 participants 
completed the full regimen of monthly monocular VF 
assessments in each eye for 6 months. One participant 
(ID P20; see table 1) discontinued after four sessions. 
Interview data were coded into four overarching themes 
relating to experiences of undertaking VF monitoring 
at home and attitudes towards its wider implementation 
in healthcare: (1) comparisons between Eyecatcher and 
HFA; (2) capability using Eyecatcher; (3) practicalities 
for effective wider scale implementation; (4) motivations 
for home monitoring. Key themes and subthemes are 
summarised in figure 3.
Table 2 Interview topic guide
COM- B model Theme Question
Capability Psychological How confident were you using the device at 
home?
Was it easy? Was it difficult? Did you become 
more confident using it over time?
Physical How do you feel you performed on the home 
visual field test compared with the test in a 
clinic? Do you think you performed differently 
between the two?
Opportunity Social When performing the visual field test at home, 
were you usually alone or were other people 
around? How did you find this compared with 
performing the test in a clinic?
Physical How would you describe performing the visual 
field test in your home setting? Were there any 
challenges caused by performing the test at 
home, specifically? Were there any benefits 
about doing the test at home, as opposed to 
in a clinic?
Motivation Automatic What, if anything, would encourage you to 
consistently complete the visual field test at 
home?
What, if anything, would prevent you 
from using the visual field test at home 
consistently?
Reflective What do you think is the value of performing 
the visual field test at home?
For whom do you think it is most appropriate 
to use home visual field testing?
If you were to do the visual field test at home 
again, what would you want to do differently? 
What would you like to keep the same?
COM- B model, Capability, Opportunity, and Motivation for Behaviour.
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Theme 1: comparisons between Eyecatcher and HFA
Testing position
Participants reported one of the biggest differences 
between Eyecatcher and conventional perimetry was the 
body position required for testing. Eyecatcher was seen to 
permit a more natural body position due to the removal 
of the chin rest and by allowing free head movement:
I find with the optician tests [HFA], I find it very dif-
ficult, it never seems possible to get my chin and my 
body and my head in the right place on it. So I'm 
always left feeling very uncomfortable during the test. 
So not having that to contend with was quite good. 
(P03)
Although the freedom of Eyecatcher testing was appre-
ciated, questions arose whether an unfixed testing posi-
tion could impact the accuracy of measurements:
While I was taking the test, I was thinking have I 
moved? Am I still in the right place? (P07)
A dislike of the enclosed environment associated 
with conventional perimetry (ie, perimeter ‘bowl’) was 
observed, and preferences for Eyecatcher’s unrestricted 
testing method were reported:
Well I don’t actually like putting my head in that 
round ball thing it’s claustrophobic. Because if they 
[HFA and Eyecatcher] are very much alike then it 
would be a much better option in my view to be home 
based doing it. (P08)
However, removal of perimeter bowl raised queries 
about distraction from peripheral stimuli present in the 
field of vision:
Looking at a laptop, there are other things within the 
field of vision in one’s own home. For example, the 
settee or the television. When I was doing it, I was 
thinking I can see the settee. Also, in an eye where 
you can’t see very well anyway, it felt like added dis-
traction. (P02)
Testing environment
Performing VF tests outside a busy clinical environment 
had perceived advantages. For example, hospital testing 
environments were considered noisy and distracting, 
whereas testing at home allowed for better control of 
these factors:
One of the things with doing it in the hospital is that 
sometimes you'll get a neighbouring patient who 
doesn't really know what they're doing. That’s unfor-
tunate, and that can be quite distracting, when you've 
got a lot of chat going on in the background, and 
you're trying to concentrate, so obviously, doing it at 
home is far, far better. (P13)
Eyecatcher visual fields were viewed as more relaxing 
due to the home environment, and it was suggested 
such measurements would likely better reflect visual 
function:
I think it’s much more comfortable, much more re-
laxing, much easier. (P08)
It’s [Eyecatcher] certainly a better experience. I felt 
as if the results should reflect my visual field better. 
I've always been a bit sceptical about the old - well, the 
current machines. (P18)
Figure 3 Coding tree showing main themes and subthemes generated from the analysis, and how different categories relate to 
each other. HES, hospital eye services; HFA, Humphrey Field Analyser; NHS, National Health Service.
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The flexibility around scheduling tests at a convenient 
time was welcomed:
I can do it when I want to do it. If I’ve got a spare half 
hour I can fit it in around other things that you’re 
doing in your life. So from that point of view you ha-
ven’t got an appointment where you’ve got to be on 
a certain day at a certain time so I prefer that. I think 
it’s because you call the shots, you decide when you 
do it, where you do it, and how you do it. So as long 
as the technicalities are clear it’s much more flexible 
which I like, yes. (P08)
Test format
Unlike conventional perimetry, Eyecatcher uses visual 
feedback (a confirmation flashing dot) indicating the 
true stimulus location after each button press. Partici-
pants had mixed opinions regarding this feedback. Visual 
feedback to confirm the stimulus was correctly identified 
was sometimes welcomed:
The great thing about this [Eyecatcher] was having 
the little white discs appear when you press the but-
ton - it makes a huge difference. With these little 
white discs appearing, I know that I've seen the white 
dot and I've correctly identified… So that does help 
enormously. (P01)
In other cases, the utility of this feedback was ques-
tioned, and participants described how it became 
distracting when the stimulus appeared in an unexpected 
location:
The little feedback flash - Now occasionally I would 
get feedback not in the place where I thought I could 
see the spot so that was a bit distracting, I think. It 
interrupted your flow. (P05)
Sometimes I’d click thinking I’d seen a light in one 
place and the confirmation light came in a different 
place, I found that a bit disconcerting. (P15)
Participants had mixed interpretations regarding the 
length of Eyecatcher tests. One participant regarded 
Eyecatcher as the faster test:
I thought I probably did better than I do in the clinic 
environment, which may be because I could concen-
trate better and I think the test was a little bit shorter 
as well. (P11)
In two cases, Eyecatcher tests were perceived to be 
longer or more variable compared with conventional 
perimetry:
The tests were of quite variable length, so I didn't 
know whether they were supposed to be that way 
or because I'd pressed something I shouldn't have 
pressed. (P09)
They seem to go on for a very long time. In the 
end, certainly by the last one, I said, you've pressed 
enough. That’s it. You've already done - I've counted 
300 attempts, you know, just leave it, you're getting 
too tired to do it. (P12)
Theme 2: capability using Eyecatcher
Confidence
There was generally a high level of confidence in using 
Eyecatcher, and this was attributed to familiarity with 
using laptops and other computer devices:
Well I was fairly confident doing that [Eyecatcher]. I 
took computer programming years ago, so I've grown 
up with computers, so that was fine. (P07)
Even among those who self- described as having limited 
computer literacy, confidence performing the test 
remained:
I was confident at performing the actual physical side 
of the test. I’m fairly limited with my IT ability and it 
was that which really caused me to be a little appre-
hensive. I had no problem with setting up the test 
and doing it. (P06)
Confidence using Eyecatcher was also attributed to 
prior experience and familiarity with VF testing on the 
whole:
I just thought it was fairly straightforward to do. I've 
done quite a few field tests in my time, so it was just 
like normal, really, for me. (P04)
For some participants, confidence in the Eyecatcher 
testing procedure accumulated after the initial tests:
It maybe took a couple just to get used to it, but it was 
fine after that. It’s quite simple. (P18)
Instruction and training
Clear testing instructions were an important resource to 
remind participants how to perform Eyecatcher tests:
The instructions were quite clear and it was quite easy 
to set up a laptop and start it off. I referred back to 
the laminated instructions each time, which was help-
ful, because I had forgotten one or two parts of it. 
(P01)
Half of the sample received a practice trial using 
Eyecatcher at baseline, which appeared to be highly 
valued. These participants described how an increased 
period of training at the start of the trial would be bene-
ficial in improving familiarity and generating confidence:
Familiarity helped, once I got the hang of it. I thought 
it would have been perhaps better to have more of 
a run- through before we got started, just to get the 
hang of it; feel that bit more confident a bit earlier in 
the experience. (P12)
In some cases, insufficient training in using Eyecatcher 
resulted in a lack of confidence and apprehension 
around the test, and this was considered a barrier to 
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home monitoring, particularly for those who may be less 
familiar with technology:
People don’t realise what a difficulty it is for older 
people like myself, who become apprehensive. The 
simplest aspect of IT you become apprehensive and 
worried about. It has to be step by step, it’s no good 
assuming that I know every single step. It has to be set 
out step by step, otherwise I fail. (P06)
You need to be able to operate, albeit in a fairly 
limited way, a PC and be aware of that basic bit of 
equipment which I think some very old people might 
struggle with possibly. (P17)
Propriety and repeatability of testing conditions
Overall, the biggest challenge for participants was 
ensuring the home environment was appropriate for 
conducting Eyecatcher tests. While all participants could 
execute the test accurately, some raised concerns whether 
environmental variations would impact measurements:
The bit that still worries me is the bit about getting 
the lighting right in the room, because there were no 
specific instructions as to how to do that. Certainly I 
found that it varied from day to day and time to time. 
I don't know at what level that impacts the results of 
the test. (P03)
I can't tell you that they were identical at all because 
the lighting I found difficult. I had to move the lap-
top around a bit and then when the darker nights ar-
rived, because I always did it in the evening, that was 
easier but then I found I couldn't see enough. (P20)
As well as difficulties optimising luminance, a further 
challenge was ensuring the laptop was at the correct 
height and distance for testing:
I was more paranoid about getting it to the right 
height, and sitting in the right place and being the 
right distance away from it, and those kinds of things. 
(P07)
Setting it up the first time is really quite tricky be-
cause if you do it at a normal work surface height, 
it’s too low. You've got to raise the machinery, so to 
speak or the – something to put the laptop on. So just 
fiddling around with that and trying to get yourself 
the right distance back and your chair in place, that’s 
quite tricky to do. (P10)
However, it was also acknowledged that testing condi-
tions for conventional perimetry are often not ideal, for 
example, the auditory disturbances described earlier. 
Creative methods were described for attempting to best 
ensure repeatability of test conditions:
Once I got the setup done and photographed it, I 
then thought well I’ll be able to do this next time, 
I’ll just do the same setup. It meant moving things 
around at home and then putting them back again. 
I photographed it and thought, well I can replicate 
this scene. (P02)
Although it was possible for all participants to perform 
Eyecatcher under suitable conditions, more flexible 
testing conditions or alternative hardware may be needed 
for wider scale implementation, such as the use of a head- 
mounted display:
The equipment itself has to change, surely. Piling up 
a laptop on wobbly books is not a way to go forward. 
You need a piece of kit that you can accurately get 
your distance that is not left to a human to set it up. 
(P16)
The ideal thing would be something you can actually 
put on your eyes, it blanks out one side and the whole 
thing works. Then you would take away some of those 
problem with light and everything else. (P03)
Visual and health-related ability
While participants described relative ease in completing 
the test, there was increased difficulty initiating the test 
for those with reduced vision in at least one eye. Problems 
arose when setting up the test while also having one eye 
occluded:
I started the test with the right eye first, I've lost vision 
in the middle of the right eye, so it’s difficult to read 
the instructions on the screen, so that was a bit awk-
ward to start the test going. (P01)
One participant described how using Eyecatcher led 
to increased symptoms of underlying vertigo. As a result, 
this participant discontinued testing after 4 months:
It didn’t really suit me. I have vertigo anyway from 
time to time, and I found that after every session of 
doing the visual field tests I was terribly dizzy. The 
usual, felt a bit sick and couldn’t get my balance prop-
erly. (P20)
Technical difficulties
A technical issue occurred whereby some devices required 
a password update. This fault was due to a software update 
which would not occur outside the context of this explor-
atory study. While this was straightforward to resolve, partici-
pants acknowledged this may be difficult for some to rectify:
I had a problem with the password. Because I'm fairly 
familiar with computers and PCs and passwords that 
wasn't a real problem, but I could understand that 
some people might become worried they'd broken it 
or something. (P17)
One solution was to develop a bespoke testing system 
where the sole purpose of the hardware is to perform the 
VF test:
If it had been programmed just to do one thing. But 
for instance, once I got into completely the wrong 
program, unbeknown. I don't what I did. (P10)
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A helpline to accommodate for software queries and 
other technical difficulties was available during office 
hours to all participants. One participant discussed its 
importance:
I did ensure that when I did the test it was on a work-
day, like a Monday to Friday because I thought there 
was a better chance of someone being at the end of 
a phone to help me get out of a pickle than there 
would be if I did it on a Saturday or a Sunday. I think 
I always would want to know that there was a helpline 
that I could ring up in case something went wrong 
with the laptop. (P02)
Theme 3: practicalities for effective wider scale 
implementation
Feedback
Two forms of important feedback on the test were 
described: verbal feedback on test performance as well 
as feedback regarding confirmation of successful comple-
tion of each test. Verbal feedback from the perimetrist 
when undertaking conventional perimetry provides valu-
able encouragement that the test is being performed 
correctly, and participants commented on the impact of 
absence of immediate feedback:
One of the things I found problematic was there 
didn't seem to be feedback. I felt a bit unfulfilled 
from that point of view. One of the differences be-
tween having it done at an optician’s and doing it 
at home is that at the optician’s, you get immediate 
feedback. Some sort of dialogue, to talk about it, to 
unpack it a bit more. (P12)
It was suggested that test- by- test feedback to confirm 
Eyecatcher tests had been appropriately performed and 
data had been received and stored successfully would be 
a valuable addition to home monitoring:
Having done that [Eyecatcher], you should then get 
an email on completion to say thanks for doing it. 
Just make it a bit two- way. I think that would be really 
good. I think that would encourage people to engage 
with it more. (P14)
Comparisons were made to other health- related 
clinic visits, such as blood donations. Greater transpar-
ency regarding the location of the test information was 
desirable:
When I've donated [blood] I get an email to say thank 
you. Then a few days later I get an email to say where 
my blood went to. It’s quite nice to get the two- way 
traffic. (P14)
Access to data and test results
The current home testing system did not allow partici-
pants to retrieve their VF measurement data. Ability to 
access Eyecatcher outputs was considered of high impor-
tance to some participants:
From the point of view of the patient, if I wasn't to 
get the results until six months later, that’s when I get 
them anyway so there’s no particular point. (P09)
It would be really nice if I could have printed the re-
sults out. But that’s just me. I can understand that 
some people wouldn't want to do that. (P14)
However, some participants noted the possible psycho-
logical effects of accessing the output:
If one was being asked to do it [Eyecatcher] as part 
of your treatment plan, it would be quite good to see 
the result. I suppose the only difficulty is that it panics 
some people. If you look at something without really 
understanding what you're looking at. They are a bit 
peculiar and that might freak you out a bit I suppose, 
which maybe isn't all terribly helpful when you're a 
layperson. (P13)
Data transfer
In the current study, participants returned the laptop 
device at the end of the trial where data were extracted. 
Questions were raised over practicalities of transferring 
Eyecatcher data to clinical review.
How is the data on the device going to be commu-
nicated? Will that be done in real time and how will 
that information get to the hospital? Is that going to 
be done by electronic transfer or emailing it? (P02)
Presumably, if this [Eyecatcher] came into common 
use, it would be linked in some way to your medical 
record, I assume the results would work with the hos-
pital record. (P13)
A possible barrier to electronic transfer of home VF 
measurements was the need for an internet connection, 
and how individuals may not have access to this service:
I’ve very intermittent wi- fi connection at home and 
so that adds another layer of complexity. If it’s ever 
going to be an interactive process where you do need 
a wi- fi connection, I can see problems. (P02)
Frequency of testing
Eyecatcher testing was performed once per month for 
this exploratory study. Some participants questioned the 
need for such regular testing intervals:
The challenge for me - because it had to be done ev-
ery month, I found was too repetitive because nor-
mally you don't have your visual fields done every 
month. (P16)
For other participants, increased regularity in 
performing the test was viewed positively, and this was 
perceived as more closely monitoring visual function. 
This is discussed further in theme 4.
Theme 4: motivations for home monitoring
Closer monitoring of eye health
While questions were raised about the necessity of monthly 
testing, home monitoring was viewed as a potential to 
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complete more regular VF tests, enabling closer moni-
toring of visual function:
I appreciate how important they [visual fields] are 
and how important they are to get a good result out 
of them. I think it is easy to broaden that and collect 
as much data as you can. Because I know that’s a real-
ly good early indicator of things deteriorating. I think 
it is very useful thing to do. I'm fully with it. (P14)
I know that glaucoma gets worse over time and I 
know that it’s important to do everything to monitor 
the progression and if something were deteriorating, 
I’d like it picked up sooner rather than later. I can 
see that doing it [visual fields] frequently, aids that 
process. (P02)
It was acknowledged that more frequent testing may 
help to mitigate issues regarding measurement accuracy. 
For example, there was a narrative of ‘getting the test 
right’ as often there may be a long time interval before 
the test will be repeated:
If there was a sudden change, I could get onto a con-
sultant quickly rather than waiting six months. Or at 
least that I would know it and at the next month’s see 
if it was really a sudden change or if I've just been too 
sleepy the last time I did it. (P09)
On a number of occasions, participants spoke openly 
about their fears the VF test is not performed as regularly 
as they would like in the hospital eye service:
I don't seem to be getting regular appointments. I 
need to keep phoning up to get my appointments at 
the hospital, I have six monthly checks and it’s been 
a year coming up in March since I have been. I like 
to have regular field tests to make sure I'm not losing 
any sight, and I think that’s quite worrying, if you've 
got this [Eyecatcher] at home, at least if that’s being 
monitored by people, it’s not such a worry. (P04)
Although closer monitoring through more frequent 
testing was welcomed, the point was raised that VF tests 
are just one component of a comprehensive glaucoma 
examination:
If I go to the glaucoma clinic, there is usually more 
than this test. So, in actual fact, if I’m just isolating to 
this type of test and not going to the hospital, then 
I’m losing out on other tests, so it might be one test 
of several. (P06)
Lower cost to NHS
It was important to participants that home monitoring 
may be a viable means of cost- saving to the NHS. This 
was due to the belief Eyecatcher was time- saving and less 
labour- intensive compared with conventional perimetry:
There’s the cost of the NHS staff to facilitate the test, 
I imagine there'd be a big saving on money for the 
NHS, which is always good. (P19)
It [Eyecatcher] has to be the way forward rather than 
sitting for hours in hospital clinics, which is wasting 
your time, but also the time of all the staff. From my 
point of view, I think that’s a huge benefit. If you 
think about the way we afford an NHS, we can't afford 
it unless we do things like this. (P10)
Less burdensome than appointment at hospital eye service
Traditional glaucoma- related hospital visits were consid-
ered time- consuming, and participants suggested home 
VF testing could partly alleviate the burden associated 
with outpatient activity:
Presumably I still have to come into a clinic at some 
stage, but it might reduce the requirement for that. It 
is quite an effort to go to an appointment at the hos-
pital, it does seem to take a lot of time really. (P03)
Home monitoring was viewed as particularly promising 
when considering the benefit to individuals with less 
accessibility to healthcare due to restricted mobility:
I can see for people who have limited mobility or if 
they have a disability of some kind it would be a great 
bonus to be able to do it from home. (P08)
Anyone who’s got mobility issues, it would be ideal if 
they were able to do it at home. (P17)
Other individuals most likely to observe benefit were 
those currently requiring two hospital attendances due to 
unsynchronised clinic appointments and consultations. 
The ability to complete VF tests at home prior to consul-
tation was viewed as a pragmatic approach to glaucoma 
monitoring:
I get two separate appointments - one for the fields 
and one for the review. I don't have a choice of 
the dates, they just send me a letter and that’s it. 
Sometimes I've gone in to review and I haven't had 
the fields test done so it’s been a waste of a review. So 
I think doing it at home is really good because you 
can do it when it’s convenient for you and also you 
can make sure you've got a fields test before you go in 
for a review. (P05)
They give me two appointments, one is for the visual 
field test and maybe another test as well and then I 
come in again to see the doctor. So I suppose doing it 
[Eyecatcher] at home would cut it down to one visit 
instead of two. (P01)
Enthusiasm for home monitoring was also amplified by 
the prospect of reduced need for travel and the associ-
ated benefit to the environment:
Of course you don't have to go anywhere. You're do-
ing it at home so good for the planet, less travel. (P17)
Self-management
Opportunity for home monitoring afforded some partici-
pants a sense of control of their glaucoma care which was 
highly valued. In comparison with hospital attendances, 
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home monitoring was described as having potential to 
create a more sustainable way of living with glaucoma:
I had a sense of control, and I think you're not put in 
the position that you are in a hospital environment 
where patients are sat in rows and treated, inevitably, 
like some sort of factory unit. So you feel that it’s the 
flip side of the responsibility, which is frightening, 
but it also encourages you to take responsibility for 
yourself in the same way as using your drops. That’s 
good, I think that you feel that there’s something you 
can do. I get a glow out of thinking that I might make 
it easier for somebody else in the future. (P10)
However, it was apparent that not everyone would view 
self- management in a positive manner. For example, 
home testing requires a high degree of patient activation:
I'm not sure everyone would be suitable for doing a 
home test. I think you have to be fairly disciplined, 
and probably quite experienced in doing them, so 
that you know really what’s supposed to happen. 
(P13)
In some cases, the idea of self- management drew nega-
tive connotations. Specifically, transference of responsi-
bility to the patient was sometimes undesirable and led to 
questions about individuals’ own role in their glaucoma 
care:
It’s much easier for me to walk into an optician’s or 
a hospital, have everything laid out, just sit down and 
do it. So, the onus isn't on the patient. (P16)
I found the responsibility for getting the setup right 
is shifted from the people in the hospital who know 
what they’re doing to a novice like me who was just 
hoping I was getting it right. (P02)
DISCUSSION
This is the first study to investigate service users’ expe-
riences of participating in a VF home monitoring 
programme. Self- selecting members of a glaucoma 
patient organisation recognised the usefulness of testing 
and valued the opportunity to have their condition moni-
tored from home. The findings suggest some individuals 
with glaucoma may embrace wider implementation of 
VF home monitoring. The significance of these findings 
is highlighted with respect to the COVID-19 pandemic, 
where conventional hospital- related outpatient activity 
cannot be easily achieved, and the potential gains of glau-
coma home monitoring are further emphasised.21
In general, participants welcomed the opportunity to 
complete more regular VF tests, as increased measure-
ment frequency was viewed as closer monitoring of 
glaucoma- related health. There was confidence that 
deterioration in visual function could be identified more 
rapidly, allowing changes in treatment if required. This 
resonated particularly among those with glaucoma under 
annual review, where there was candid discussion about 
concerns over delays in receiving appointments and 
lengthy time intervals between measurements. Delayed 
follow- up due to hospital- initiated appointment resched-
uling has been reported as a significant cause of VF loss 
in patients with glaucoma,22 and use of VF home testing 
may help to mitigate such instances in future. However, 
some participants questioned the necessity of monthly VF 
measurements, and although acceptable in the context 
of a research study, they risk becoming a nuisance if 
required long term. Our rationale for monthly testing 
was linked to investigating feasibility, as opposed to 
determining clinical need. Multiple studies have shown 
that intensive VF testing can help identify and prioritise 
individuals most at risk of rapid sight loss,4–6 and there is 
convincing evidence that three VF tests per year provide 
adequate information to aid clinical decision- making.23 
Further assessment of the optimal number of home VF 
measurements is required. Applying a targeted approach 
to patient selection, where home monitoring of those at 
greatest risk of debilitating visual loss based on individ-
ual’s age,4 condition,24–26 ethnicity1 or socioeconomic 
status,27 could maximise the potential benefits of home 
VF monitoring.
A further concern regarding the conventional 
approach to VF testing was the issue of performance pres-
sure, and how limited opportunities to perform the test 
gave credence to beliefs about needing to ‘get the test 
right’. Specifically, concerns about how lethargy might 
impact on measurement outcomes were reported, and 
similar findings have been observed elsewhere.28 Greater 
capacity to highlight spurious results through more 
frequent testing was considered an advantage. Similarly, 
home testing allowed participants to complete measure-
ments at their convenience. It was thought that testing in 
these circumstances would likely better reflect true visual 
function, as extraneous variables such as energy levels 
could be better controlled. For example, participants 
could complete tests when feeling at peak performance 
using Eyecatcher, whereas conventional testing relies on 
designated testing times. Indeed, transient factors such as 
fatigue, lack of concentration, or delayed reaction time 
can significantly obscure VF measurements and increase 
variability.29 Although our findings suggest participants 
exhibited similar testing behaviour and outcomes between 
Eyecatcher and HFA,15 we highlight that flexibility around 
performing VF tests is of value to people with glaucoma, 
representing a more quality- oriented approach toward 
individual patient needs and preferences.
Participants generally compared Eyecatcher positively 
with conventional perimetry. In particular, the absence of 
chin and head restraints with Eyecatcher was particularly 
preferred over the HFA, which was viewed as an uncom-
fortable and unnatural testing procedure. There was a 
diversity of opinions, however, and some participants 
did question whether Eyecatcher’s more relaxed testing 
procedure, and/or the lack of a conventional perimetric 
bowl (to occlude potential distractions), may result in 
more distractions and less reliable measurements. Our 
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quantitative analysis suggests the home monitoring data 
were generally of good quality, and that any loss of reli-
ability was largely compensated for by the overall increase 
in the volume of data.15 However, distractions will always 
be a concern for any unsupervised/uncontrolled testing. 
In response to this, we have developed computer- vision, 
AI technology to autonomously detect and account for 
lapses in concentration. This technology uses data from 
the web cam on the portable device and can be embedded 
within Eyecatcher. Our investigation of this technology 
in a large group of people, although with healthy 
vision, is the subject of a report published elsewhere.30 
More generally, the fact that there were mixed opinions 
regarding the Eyecatcher interface (ie, with some finding 
the removal of the bowl liberating, while others expressed 
concerns regarding increased distractions) highlights the 
inherent complexities associated with developing and 
implementing novel health- related technologies and 
ensuring they match the needs and preferences of the 
target users. We hope that the in- depth feedback gener-
ated in this study will serve as a useful reference for clini-
cians, researchers and commissioners working in the area 
of VF home monitoring.
Several participants noted that test durations were often 
longer and more variable than with standard automated 
perimetry. This is true. Median test durations were 4.5 min 
vs 3.9 min for HFA (SITA Fast), and a minority of indi-
vidual tests lasted as long as 10 min.15 These differences 
are not intrinsic to home monitoring, but rather reflect 
the fact that Eyecatcher is at present a crude prototype, 
that has not been optimised in the same way as modern 
commercial perimeters (see Jones et al for detailed tech-
nical suggestions15). It is highly encouraging though that 
people nevertheless found home monitoring positive and 
desirable, despite current technical shortcomings.
Participants recognised the possible economic value of 
home monitoring, especially in terms of saving costs in 
the NHS. In particular, time and resource- saving poten-
tial of remote testing was viewed very positively. Previous 
research suggests people with glaucoma generally approve 
of service- level cost- saving, so long as it is in tandem with 
improved efficiency and efficacy.31 Moreover, perceived 
financial worth of home testing may serve as behavioural 
encouragement to adhere to prescribed testing regimens. 
Conversely, it should be noted that home monitoring itself 
has associated costs, and the extent to which home moni-
toring of VFs is cost- effective is yet to be established.32 
Prospective costs associated with VF home monitoring 
include data management and the cost of supplying and 
maintaining any associated hardware (though exactly 
what hardware is required, or whether a perimetry test 
could even be provided simply as a ‘downloadable app’ 
remains an unresolved question and highly contentious). 
Home monitoring provides opportunity for increased 
frequency of VF testing, which may place a burden on 
clinicians. Considering previous estimations of costs asso-
ciated with conventional VF testing,33 we predict home 
VF testing will prove cost- effective, at least for the most 
high- risk patients (eg, younger individuals or those with 
risk factors for fast progression). A formal economic eval-
uation is required, however.
In addition to service- level economic value, participants 
associated home VF testing with personal savings such as 
reduced transportation to clinic which can be costly.34 
Financial aspects of home monitoring are particularly 
relevant to those with unsynchronised testing and consul-
tation appointments, which usually duplicates costs. This 
finding emphasises the potential gains associated with 
home monitoring in ophthalmology, including direct 
financial savings to patients. Indirect costs to patients asso-
ciated with hospital visits included the general burden of 
lengthy hospital visits which typically rely on assistance 
from an informal caregiver. Evidence suggests compan-
ionship during eye- related hospital outpatient visits may 
have substantial ‘unseen’ consequences, such as imposed 
strain on social relationships.35 36 While home moni-
toring will not obviate the need for hospital attendances, 
participants viewed it as an opportunity to streamline the 
glaucoma service. Home monitoring can be useful to 
augment conventional outpatient activity and help indi-
cate when other glaucoma- related measurements need 
to be prioritised. It is noteworthy that when comparing 
home monitoring of their VFs with monitoring in a clinic 
environment, participants sometimes referred to VF tests 
conducted in/by opticians in addition to those carried 
out in the hospital eye service. This is unsurprising given 
that when people with glaucoma attend their community 
optometrist for a routine sight test, a VF test (often using 
the same or similar equipment to that used in hospital eye 
service) is normally carried out.
Eighteen (90%) participants discussed their experi-
ences of ensuring the VF tests were performed under 
the appropriate conditions at home, such as under dim 
lighting while positioned at eye level with the laptop 
perimeter. Despite all participants successfully completing 
VF tests at home and to a good standard, there were 
some concerns about the propriety and repeatability of 
the testing conditions. Our parallel investigation demon-
strated no relationship between changes in illuminance 
and changes in VF test score, or between absolute illu-
minance and absolute test score, suggesting luminance 
had little effect on the study data.15 It is possible that a 
period of training to familiarise with Eyecatcher may reas-
sure patients about the testing conditions and procedure. 
However, there appeared to be no major differences in 
difficulties experienced throughout the study between 
those receiving a demonstration at baseline compared 
with those without.
Wider scale implementation of home VF testing attracted 
questions about transference of test data to care providers 
and storage within patient clinical records. In the current 
study, remote access to the laptop perimeters was disabled, 
thus data extraction was only possible upon returning the 
device at the end of the study. A system automatically expe-
diting data for clinical review could provide a more pragmatic 
approach to VF home monitoring, and has been adopted in 
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remote monitoring of other health conditions.37 Previous 
approaches to portable perimetry have developed appli-
cations (eg, Melbourne Rapid Fields11) notifying treating 
clinicians if a significant change in vision has been detected. 
Inclusion of a remote data access feature would be relatively 
straightforward to implement in future studies. Our partici-
pants acknowledged barriers relating to transference of data, 
stating this should be an automated process and not require 
additional responsibilities for the service user. It would be 
pragmatic to use a device compatible with internet accessi-
bility whereby data are transferred direct for clinical review.
Our sample contained a range of older adult ages (62–78 
years), and the vast majority reported ease using Eyecatcher. 
It may be argued that individuals in the later stages of life 
would not necessarily benefit from increased monitoring, 
because the likelihood of patients suffering with visual 
impairment is linked to the rate of glaucomatous progres-
sion and extent of VF loss at presentation.4 There was a 
belief among participants that some elderly people with glau-
coma may struggle with using home monitoring technology. 
Evidence suggests older people engage better with tech-
nologies that are considered to have value, including those 
enabling self- monitoring.38 Patterns of technology usage 
suggest older ophthalmic patients frequently use technology, 
for example, 88.5% of people aged 66–79 years attending 
Manchester Royal Eye Hospital report regularly using tech-
nologies including desktop and laptop computers.39 Many 
older adults aged 65 years and over use devices relating to 
healthcare, such as glucose and cardiac monitoring tools.40 It 
is perhaps most appropriate to expect large variability in abili-
ties relating to technology among older populations. Indeed, 
increased variation in physical and cognitive function as 
people age requires healthcare policies to consider service 
users on a more individual basis.41 Thus, a patient self- select 
approach may be the most practical means of best ensuring 
effective implementation of home VF monitoring. As one 
participant in this study described it, ‘I would be very loath to 
rule people out, and people surprise you all the time’ (P10).
Issues relating to inability to view measurement results were 
raised by one participant. As the name would suggest, home 
monitoring devices should allow users the opportunity to 
view measurement outcomes. In this study, participants did 
not have access to their study data, leading to reduced moti-
vation to complete the test for this participant. Access to test 
results is important to patients,42 and people with glaucoma 
are often very interested to learn about their VF results.28 
This raises a number of important questions around what 
information would be meaningful, useful and actionable for 
patients. Evidence suggests direct release of test results is asso-
ciated with increased healthcare engagement.43 However, 
unintended consequences which must be considered include 
increased anxiety regarding unusual results,13 and the ethical 
implications of providing complex clinical data outside of 
a hospital or clinic environment, where queries cannot be 
addressed promptly. This problem is arguably more acute 
in glaucoma due to the large amount of technical detail 
provided in each VF report, interpretation of which requires 
specialist knowledge. One potential solution is to offer a 
high- level overview of results accessible via an online portal 
or downloadable app, although this would also require tech-
nical expertise and should be explored in further research. 
In addition to providing transparency regarding test results, 
such a service may encourage behavioural reinforcement 
to consistently complete VF testing at home, while also 
providing confirmation of successful completion of the test.
Our findings highlighted that greater responsibility 
through home testing was empowering for some partici-
pants, and may encourage a sustainable approach to living 
with glaucoma. However, two participants preferred conven-
tional in- clinic VF testing rather than at home. In that respect, 
an assessment of individual self- efficacy regarding personal 
health management may help to prioritise individuals 
where home monitoring is most likely to be tolerated and 
successful. There may also be opportunity to encourage self- 
management behaviours through ‘Expert Patient Initiatives’ 
which have been shown to be successful in helping patients 
develop new health- related skills and promote active patient 
involvement in care.44
The present study explored experiences of home VF 
testing over 6 months; it remains unknown if favourable 
opinions and compliance persist long term. Yet, home moni-
toring would not necessarily be for life and might be most 
beneficial for the first 2 years following diagnosis.33 The 
study was designed to collect monthly VF measurements, 
which is more frequent than typical VF monitoring, further 
research assessing patient interaction with glaucoma home 
monitoring over an extended time period is warranted. Our 
study measured VFs using a variant of the Eyecatcher test,12 16 
however there is no reason to expect that the findings would 
differ between other VF home monitoring systems.
The primary limitation of the present study is the fact 
that participants were self- selecting and, as a result, highly 
motivated and relatively homogeneous. All participants 
were members of a glaucoma charity organisation and 
were highly engaged with their eye health. The ability, 
and motivation, to undertake home perimetry, as well as 
the opinion of telemedicine in general, may be consider-
ably lower in the general population. Further, while our 
sample included people with a range of ages, geograph-
ical locations and VF loss severities, it was comprised 
solely of Caucasian individuals who had the time and 
motivation to engage with research. We did not examine 
the impact of individual differences in socioeconomic 
status, lifestyle, health literacy, or various cultural or 
linguistic factors, each of which could impact the feasi-
bility and acceptability of home VF testing substantively. 
Finally, due to the longitudinal nature of the research, 
our results may also be influenced by recall bias (ie, poor 
accuracy of participants’ recollection); however, given the 
consistency in responses across interviews, we believe that 
the overall message of the report remains accurate.
In summary, our self- selecting participants with glau-
coma were widely accepting and highly capable of home 
VF testing, and this may partly be explained by a combi-
nation of perceived benefits and motivations. Participants 
believed home monitoring may help to improve service 
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delivery, and Eyecatcher was compared positively with 
conventional perimetry. There are certain barriers to 
home VF monitoring such as unfamiliarity with bespoke 
testing devices and measurement features, yet these 
issues do not appear to be insurmountable. This report 
describes the experience of home monitoring among the 
target population. Details regarding patient preferences 
and attitudes can be used to inform future study design 
and guide current strategies to maximise the effectiveness 
of home monitoring programmes and help build a more 
sustainable glaucoma service infrastructure.
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